Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > enough suits!
View:
Post by kalman007 on Feb 03, 2022 10:45am

enough suits!

personally, i don't really care about the new board appointments.  i want to see positive clinical results final approval of PMN 310 and then a huge pharma play.  they promised this on the road map years ago but have failer to deliver anything. these guys may be smart but geez, the runway keeps getting longer.  they can't seem to execute!  i still have faith in PMN but they had better release some other news, or invester interest could wane, if it hasn't already
Comment by DavidKingCanada on Feb 03, 2022 11:15am
With each Suit we add more to Payroll. Enough horsing around already, we still have not received any sort of Outook for 2022! Price as been stagnant at 0.13 CAD and will probably dip if we dont see any short term goals or any Legit Deals put in place. 
Comment by azzymaa on Feb 03, 2022 11:39am
Still waiting for the Stock to hit 0.15
Comment by bball67 on Feb 03, 2022 12:04pm
David, why are you putting out misinformation again. Very accomplished scientists and doctors being referred to as "suits" is insulting to the individuals and their professional careers. The Scientific Advisory Board is not the Board of Directors. They serve in an adivisory role and are not on the payroll. You may have noticed that there have been many additions recently which relate to ...more  
Comment by M101 on Feb 03, 2022 12:40pm
Seems like semantics, for me they're not wearing lab coats so they're suits by default. Maybe for you suits handle money, well they may not be on the payroll but they will certainly get paid.  Other than that I agree with you. 
Comment by azzymaa on Feb 03, 2022 12:54pm
Bball, you forgot to mention Kalman also called them Suits. Why are you only pointing at David? 
Comment by DavidKingCanada on Feb 03, 2022 12:59pm
Because of Bball has lost a significant amount of Money betting on a Penny stock at all time high and is now crying a like a little kid who lost his Mom at the supermarket.  At 0.16 I will be at 60% Gains. How about yourself? Negative 600% Loss?  Get a life and learn to Invest in Penny Stocks especcially Pharma the correct way and not when the Stock is at a all time high without any ...more  
Comment by bball67 on Feb 03, 2022 1:22pm
Hey King David. No reply about your misstatement about the Advisory Board being on payroll? No reply about your misstatement about the three billionaires selling their Promis stock?  David, to lose money you have to sell a stock. I own 1.43M shares at .15 US. Have never sold the stock. This investment like 1% if my net worth. Those who are long term holds will be richly rewarded. This is ...more  
Comment by DavidKingCanada on Feb 03, 2022 2:01pm
This is the reason this board is full of Jokers when you have "InVeStOrS" like Bball claiming their Networth is north of $21,000,000.00 USD. I stay here for the laughs! 
Comment by azzymaa on Feb 03, 2022 4:09pm
hey bball, why wouldn't the sab be on the payroll? Are they doing this for free? explain why they would not be on the payroll and be paid well? also, if you have over 21 million in the bank then why are you on here lol wouldn't you have some sort of advisor taking care of your money? let me guess you are also self made millionaire 
Comment by Gbathat on Feb 04, 2022 8:11am
BBall, I agree that these are interesting additions to the SAB, especially given their hospital affiliations. The quote attributed to Dr. Cashman mentioned "broad" exerptise in neuro, but I suspect they were brought on for very specific reasons- advisement on clinical trial coordination from someone who manages a neuro-focused hospital, and advisement on collection and review of ...more  
Comment by Speyeder999 on Feb 04, 2022 9:55am
Well said Gbathat, I'm along on the same ride. So thanks for that! (you too BBall) GLTA
Comment by M101 on Feb 04, 2022 12:24pm
But those needs come after selecting the protein(s), the conformation specific epitopes, and producing the antibodies. So if you are right then Gene should be able to provide us with development timeline much faster than we've experienced.  I suspect these appointments arise now simply because money is finally available and Cashman has wanted to expand in this direction for a while.  ...more  
Comment by M101 on Feb 03, 2022 12:27pm
Yeah, too many suits. Apparently SAB appointments = exec gig work. Rouleau seems like a big name, too big to be hands on so I guess it's about prestige and connections.  But why Dagher, functional brain imaging?  This is obviously not just about schizophrenia, it's about every mental illness for which misfolded proteins are suspect. So it's a major foray into mental illness ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities